Table of Contents
Bullous Pemphigoid - Pipeline Review, H2 2016
Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Bullous Pemphigoid – Pipeline Review, H2 2016, provides an overview of the Bullous Pemphigoid (Dermatology) pipeline landscape.
Bullous pemphigoid is a chronic, inflammatory, subepidermal, blistering disease. If untreated, it can persist for monthsor years, with periods of spontaneous remissions and exacerbations. The disease can be fatal, particularly in patientswho are debilitated.
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Bullous Pemphigoid – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Bullous Pemphigoid (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Bullous Pemphigoid (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Bullous Pemphigoid and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2 and 1 respectively.
Bullous Pemphigoid (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Bullous Pemphigoid (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Bullous Pemphigoid (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bullous Pemphigoid (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bullous Pemphigoid (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bullous Pemphigoid (Dermatology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bullous Pemphigoid (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bullous Pemphigoid (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Get Industry Insights. Simply.
Talk to Veronica
+1 718 514 2762
Dermatology Therapeutics Drug Development Pipeline Review, 2016 Summary Dermatological conditions are one of the most common types of disorders worldwide, and approximately one-third of the US population ...
Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) - Pipeline Review, H2 2016 Summary Global ...
Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Intercellular Adhesion Molecule 1 (Major Group Rhinovirus ...